Wayne AUSTIN · Prevention of Future Deaths report

Pin Get email alerts Request correction

Issued 10 Apr 2026•Shropshire, Telford and Wrekin

Published report and response evidence

This report’s concerns and statements found in recipients’ published responses. Statements are included even where no link to an individual concern is recorded. A link shows an evidence connection; it does not assign responsibility.

View original report
Concerns
3

Raised in this report

Recipients
2

Named on the report

Responses found
2

Of 2 recipients

Stated actions
8

Described in responses

Full report text

This is the full text from the original published report.

Open published report

Concerns and recipient responses

Select any concern, action or position to view the source wording.

Report evidence summary

Concerns raised3

  1. Difficulties in locating the appropriate cardiac-arrest Naloxone guidance on the JRCALC app
    Part of recurring concern: Unreliable antidote treatment arrangements for toxic-substance poisoningPart of recurring concern: Unsafe access to and application of Naloxone guidance
  2. Insufficient Naloxone stock carried per ambulance for opioid-related cardiac arrest
    Part of recurring concern: Failure to ensure paramedics have required emergency medicines for pre-hospital carePart of recurring concern: Unreliable antidote treatment arrangements for toxic-substance poisoning
  3. Inability of attending paramedics to comply with opioid-related respiratory-arrest and cardiac-arrest guidelines amid competing tasks
    Part of recurring concern: Unreliable resuscitation preparedness and response during cardiac arrest

Stated actions An action is something a recipient says it has done, is doing, or plans to do in response to a concern raised.8

  1. West Midlands Ambulance Service University NHS Foundation Trust

    Raise the practical and evidential concerns about cardiac-arrest Naloxone Hydrochloride guidance with JRCALC for consideration in its guidance review.

  2. West Midlands Ambulance Service University NHS Foundation Trust

    Complete formal clinical reviews of ambulance Naloxone Hydrochloride quantities and confirm the current ten-ampoule load list remains appropriate.

  3. Association of Ambulance Chief Executives

    Remove naloxone use during cardiac arrest from the JRCALC guidance.

  4. Association of Ambulance Chief Executives

    Approve changes to the naloxone monograph in response to the concerns raised.

  5. Association of Ambulance Chief Executives

    Review the naloxone monograph.

  6. Association of Ambulance Chief Executives

    Introduce the approved naloxone changes into ambulance service clinical practice guidelines, subject to approval.

  7. Association of Ambulance Chief Executives

    Have the agreed naloxone changes reviewed by the national ambulance service medical directors group.

  8. Association of Ambulance Chief Executives

    Standardise all JRCALC drug monographs through the Medicines Governance Group.

Respondent positions A position is what a recipient says about a concern when it does not describe a specific action.8

  1. West Midlands Ambulance Service University NHS Foundation Trust

    The recommended maximum naloxone stock is not a realistic operational benchmark because benefit during established cardiac arrest is limited and uncertain.

    Disputes the concernThe respondent disagreed with part of the concern or the basis for it.
  2. West Midlands Ambulance Service University NHS Foundation Trust

    The current load-list quantity of 10 naloxone ampoules per ambulance is considered appropriate for respiratory arrest or respiratory depression.

    Existing arrangements considered sufficientThe respondent said that existing arrangements were sufficient, so no further action was needed.
  3. West Midlands Ambulance Service University NHS Foundation Trust

    JRCALC and Class Publishing are responsible for resolving the app’s format, navigation and usability issues.

    Redirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
  4. West Midlands Ambulance Service University NHS Foundation Trust

    Full adherence to repeated naloxone dosing during cardiac arrest is impracticable because of task saturation and competing life-saving interventions.

    Unable to actThe respondent said that a constraint prevented them from taking the relevant action.
  5. West Midlands Ambulance Service University NHS Foundation Trust

    JRCALC and Class Publishing are responsible for resolving concerns about the naloxone cardiac-arrest guideline.

    Redirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
  6. West Midlands Ambulance Service University NHS Foundation Trust

    Increasing naloxone stock would impose significant logistical and financial burdens disproportionate to its limited and uncertain cardiac-arrest benefit.

    Unable to actThe respondent said that a constraint prevented them from taking the relevant action.
  7. Association of Ambulance Chief Executives

    NASMeD is responsible for reviewing and approving the agreed naloxone guideline changes before their introduction into ambulance practice.

    Redirects responsibilityThe respondent said that another organisation was responsible for deciding or taking action.
  8. Association of Ambulance Chief Executives

    Increasing naloxone stocks is unnecessary because naloxone will no longer be recommended during opioid-related cardiac arrest.

    No action considered necessaryThe respondent said that no further action was needed.

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Difficulties in locating the appropriate cardiac-arrest Naloxone guidance on the JRCALC app

Wider context from the report

“(1) Difficulties in locating the appropriate tab for cardiac arrest (where opioid toxicity is the likely cause) on the JRCALC app for Naloxone meant it was missed and not applied ”

Is this part of a recurring concern?

Yes — Unreliable antidote treatment arrangements for toxic-substance poisoning; Unsafe access to and application of Naloxone guidance.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Insufficient Naloxone stock carried per ambulance for opioid-related cardiac arrest

Wider context from the report

“(3) WMAS ambulances only carry a box of 10 Naloxone 400mg vials per ambulance which means that one ambulance attending a situation such as Wayne’s would be insufficient to deal with the circumstances, as would two ambulances. It would mean that three ambulances are required to comply with cardiac arrest (where opioid toxicity is the likely cause). ”

Is this part of a recurring concern?

Yes — Failure to ensure paramedics have required emergency medicines for pre-hospital care; Unreliable antidote treatment arrangements for toxic-substance poisoning.

Open source report

Source evidence

How this individual concern was interpreted

PFD Monitor created a concise, searchable interpretation from the report wording shown below. Response links show a clear evidence connection; they do not assign responsibility.

PFD Monitor interpretation

Inability of attending paramedics to comply with opioid-related respiratory-arrest and cardiac-arrest guidelines amid competing tasks

Wider context from the report

“(2) Inability of attending paramedics to comply with the guidelines for Respiratory arrest/depression due to other competing tasks and therefore certainly a complete inability to comply with the guidelines for cardiac arrest (where opioid toxicity is the likely cause) making them potentially unrealistic. ”

Is this part of a recurring concern?

Yes — Unreliable resuscitation preparedness and response during cardiac arrest.

Open source report

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Raise the practical and evidential concerns about cardiac-arrest Naloxone Hydrochloride guidance with JRCALC for consideration in its guidance review.

Verbatim wording from the response

“Overall, this issue reflects a disconnect between guideline intent and what is operationally achievable during cardiac arrest resuscitation, rather than an unreasonable failure to follow guidance. WMAS considers that, in this context, the guideline may not be fully realistic for frontline application and should be interpreted pragmatically, with patient-centred prioritisation of core life-saving interventions. The WMAS Medical Director has raised these points with JRCALC, and it is our understanding that the Naloxone Hydrochloride guidance will be reviewed.”

Source location

Response from West Midlands Ambulance Service
Page 3 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Complete formal clinical reviews of ambulance Naloxone Hydrochloride quantities and confirm the current ten-ampoule load list remains appropriate.

Verbatim wording from the response

“WMAS has undertaken formal clinical review of this issue. An initial review of Naloxone Hydrochloride quantities was completed in May 2025 by the WMAS Consultant Paramedic for Emergency Care, followed by a further review in September 2025 by the senior clinical team. The latter specifically considering the cardiac arrest guidance where opioid overdose is suspected. The consensus from the latest review was that the current Naloxone Hydrochloride quantities carried on the WMAS Load List were appropriate.”

Source location

Response from West Midlands Ambulance Service
Page 4 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Remove naloxone use during cardiac arrest from the JRCALC guidance.

Verbatim wording from the response

“The JRCALC committee has approved the removal of the use of naloxone during cardiac arrest. The evidence that naloxone improves survival once cardiac arrest has occurred is limited. Furthermore, it may distract the attending clinicians from more important tasks such as early defibrillation, high quality chest compressions and effective ventilation. The use of naloxone will remain indicated for the reversal of acute opioid or opiate toxicity for respiratory arrest or respiratory depression; this is detailed in several of our clinical guidelines. We have also contacted the UK National Poisons Information Service to discuss the recommended cardiac arrest management for opioid poisoning.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 2 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Approve changes to the naloxone monograph in response to the concerns raised.

Verbatim wording from the response

“We are currently working on standardising all drug monographs through our Medicines Governance Group to ensure that all medicines monographs within JRCALC meet legal, regulatory, and good practice requirements. The naloxone monograph is currently under review, and we have shared the matters of concern with the lead person for the drug monograph and the JRCALC committee who have approved changes in response to your concerns.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 1 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Review the naloxone monograph.

Verbatim wording from the response

“We are currently working on standardising all drug monographs through our Medicines Governance Group to ensure that all medicines monographs within JRCALC meet legal, regulatory, and good practice requirements. The naloxone monograph is currently under review, and we have shared the matters of concern with the lead person for the drug monograph and the JRCALC committee who have approved changes in response to your concerns.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 1 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Introduce the approved naloxone changes into ambulance service clinical practice guidelines, subject to approval.

Verbatim wording from the response

“The changes agreed to the use of naloxone by the JRCALC committee will be reviewed by the national ambulance service medical directors group (NASMeD) and, subject to approval, will subsequently be introduced into ambulance service clinical practice guidelines.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 2 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Have the agreed naloxone changes reviewed by the national ambulance service medical directors group.

Verbatim wording from the response

“The changes agreed to the use of naloxone by the JRCALC committee will be reviewed by the national ambulance service medical directors group (NASMeD) and, subject to approval, will subsequently be introduced into ambulance service clinical practice guidelines.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 2 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent action was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Standardise all JRCALC drug monographs through the Medicines Governance Group.

Verbatim wording from the response

“We are currently working on standardising all drug monographs through our Medicines Governance Group to ensure that all medicines monographs within JRCALC meet legal, regulatory, and good practice requirements. The naloxone monograph is currently under review, and we have shared the matters of concern with the lead person for the drug monograph and the JRCALC committee who have approved changes in response to your concerns.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 1 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

The recommended maximum naloxone stock is not a realistic operational benchmark because benefit during established cardiac arrest is limited and uncertain.

Verbatim wording from the response

“WMAS acknowledges that, based on the JRCALC cardiac arrest guidance, where opioid toxicity is considered the likely cause, the cumulative Naloxone Hydrochloride dose required would exceed the stock carried on a single ambulance, and a second ambulance. However, WMAS does not consider this to represent a realistic or operationally appropriate benchmark against which the WMAS Drug Load List should be assessed.”

Source location

Response from West Midlands Ambulance Service
Page 4 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

The current load-list quantity of 10 naloxone ampoules per ambulance is considered appropriate for respiratory arrest or respiratory depression.

Verbatim wording from the response

“WMAS has undertaken formal clinical review of this issue. An initial review of Naloxone Hydrochloride quantities was completed in May 2025 by the WMAS Consultant Paramedic for Emergency Care, followed by a further review in September 2025 by the senior clinical team. The latter specifically considering the cardiac arrest guidance where opioid overdose is suspected. The consensus from the latest review was that the current Naloxone Hydrochloride quantities carried on the WMAS Load List were appropriate.”

Source location

Response from West Midlands Ambulance Service
Page 4 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

JRCALC and Class Publishing are responsible for resolving the app’s format, navigation and usability issues.

Verbatim wording from the response

“The Naloxone Hydrochloride guidance within the JRCALC PLUS App is authored by JRCALC and digitally formatted and published by Class Publishing. WMAS do not have the ability to customise the format, layout, or navigation structure of the JRCALC PLUS App. This includes the location of drugs, the tabs used to access them, and the presentation of reference tables. These design and structural elements are determined centrally by JRCALC and Class Publishing and are applied consistently across all subscribing ambulance services.”

Source location

Response from West Midlands Ambulance Service
Page 2 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Full adherence to repeated naloxone dosing during cardiac arrest is impracticable because of task saturation and competing life-saving interventions.

Verbatim wording from the response

“WMAS recognises that, in the context of an active cardiac arrest, achieving this dosing regimen is not realistically achievable. Cardiac arrest management requires the simultaneous delivery of multiple time-critical interventions, including high-quality CPR, airway management, ventilation, rhythm recognition, defibrillation where appropriate, vascular access, drug preparation and administration, and team leadership. Unless multiple additional clinicians are present with a designated role focused exclusively on the repeated preparation, checking, and administration of Naloxone Hydrochloride, compliance with this aspect of the guideline is not practicable during resuscitation.”

Source location

Response from West Midlands Ambulance Service
Page 3 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

JRCALC and Class Publishing are responsible for resolving concerns about the naloxone cardiac-arrest guideline.

Verbatim wording from the response

“Overall, this issue reflects a disconnect between guideline intent and what is operationally achievable during cardiac arrest resuscitation, rather than an unreasonable failure to follow guidance. WMAS considers that, in this context, the guideline may not be fully realistic for frontline application and should be interpreted pragmatically, with patient-centred prioritisation of core life-saving interventions. The WMAS Medical Director has raised these points with JRCALC, and it is our understanding that the Naloxone Hydrochloride guidance will be reviewed.”

Source location

Response from West Midlands Ambulance Service
Page 3 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Increasing naloxone stock would impose significant logistical and financial burdens disproportionate to its limited and uncertain cardiac-arrest benefit.

Verbatim wording from the response

“There are also practical considerations related to medicine supply resilience. Naloxone Hydrochloride has previously been subject to national supply constraints. Increasing carriage to 25 ampoules per ambulance, alongside maintaining sufficient reserve stock to support fleet-wide replenishment, would present a significant logistical and financial burden. When weighed against the limited and uncertain benefit of Naloxone Hydrochloride in cardiac arrest, this does not represent a proportionate risk-benefit or cost-benefit intervention.”

Source location

Response from West Midlands Ambulance Service
Page 4 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

NASMeD is responsible for reviewing and approving the agreed naloxone guideline changes before their introduction into ambulance practice.

Verbatim wording from the response

“The changes agreed to the use of naloxone by the JRCALC committee will be reviewed by the national ambulance service medical directors group (NASMeD) and, subject to approval, will subsequently be introduced into ambulance service clinical practice guidelines.”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 2 · response
Published 17 April 2026

Open published response

Source evidence

How this respondent position was interpreted

PFD Monitor created a concise, searchable interpretation from the published response wording shown below.

PFD Monitor interpretation

Increasing naloxone stocks is unnecessary because naloxone will no longer be recommended during opioid-related cardiac arrest.

Verbatim wording from the response

“3) WMAS ambulances only carry a box of 10 Naloxone 400mg vials per ambulance which means that one ambulance attending a situation such as Wayne’s would be insufficient to deal with the circumstances, as would two ambulances. It would mean that three ambulances are required to comply with cardiac arrest (where opioid toxicity is the likely cause).”

Source location

Response from Association of Ambulance Chief Executives (on behalf of the Joint Royal Colleges Ambulance Liaison Committee)
Page 2 · response
Published 17 April 2026

Open published response
Back to top

Information checked against the published report and official responses · Data reviewed 7 Sep 2026 · About data quality and limitations

Official responses located
2/2

Data last updated 7 September 2026